

Freedom of Information Act 2000 - Request Reference Fol/20/103

Anti VEGF Therapy

Request details

1. Within your trust how many patients over the last 12 months have received treatment with an anti VEGF therapy, who had not previously had anti VEGF therapy?

2. How many of these [from question 1] patients have received the following anti VEGF therapy in the last 12 months?

Ranibizumab

Bevacizumab

Aflibercept

Fluocinolone

Dexamethasone

3. Of the patients above, how many were treated for Wet Age Related Macular Degeneration (wAMD) ?

Ranibizumab

Bevacizumab

Aflibercept

Fluocinolone

Dexamethasone

Response details

In completing a search for the information requested, Cardiff and Vale University Health Board (the UHB) has confirmed that this information is not centrally recorded or collated. To retrieve the information requested would require a manual search through individual records and the UHB considers that this would exceed the limit set within regulations for responding to a request. The UHB has therefore relied upon the Section 12 exemption ('Exemption where cost of compliance exceeds appropriate limit') of the Freedom of Information Act 2000 and is refusing your request.

The UHB has estimated that to complete the work needed to respond to this request would exceed the time limit as set within regulations to respond to a Freedom of Information Act request. Under the Act there is an allowance of two and a half days, or 18 hours, to comply with a request and the cost limit set within the fees regulations for this amount of work (18 hours) is £450 for the UHB. The fees regulations specify that the cost of complying with a request must be calculated at the rate of £25 per hour.

To comply with our Section 16 obligation, the duty to provide advice and assistance, I would like to inform you that the UHB can provide data for Clinic 7 patients only, booked directly into AMD new case clinics, please find this information below:

1. Within your trust how many patients over the last 12 months have received treatment with an anti VEGF therapy, who had not previously had anti VEGF therapy?

166

2. How many of these [from question 1] patients have received the following anti VEGF therapy in the last 12 months?

Ranibizumab - **143 (Lucentis)**

Aflibercept - **23 (Eylea)**

3. Of the patients above, how many were treated for Wet Age Related Macular Degeneration (wAMD) ?

Ranibizumab: **143 (Lucentis)**

Aflibercept: **23 (Eylea)**